Iwasaki A, Medzhitov R: Regulation of adaptive immunity by the innate immune system. Science. 2010, 327: 291-295. 10.1126/science.1183021.
Article
PubMed Central
PubMed
Google Scholar
Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol. 2004, 4: 499-511. 10.1038/nri1391.
Article
PubMed
Google Scholar
Janeway CA, Medzhitov R: Innate immune recognition. Annu Rev Immunol. 2002, 20: 197-216. 10.1146/annurev.immunol.20.083001.084359.
Article
PubMed
Google Scholar
Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol. 2001, 1: 135-145. 10.1038/35100529.
Article
PubMed
Google Scholar
Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature. 2000, 406: 782-787. 10.1038/35021228.
Article
PubMed
Google Scholar
Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF: Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology. 2007, 46: 1769-1778. 10.1002/hep.21897.
Article
PubMed
Google Scholar
Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005, 5: 215-229. 10.1038/nri1573.
Article
PubMed
Google Scholar
Talwani R, Gilliam BL, Rizza SA, Nehra V, Temesgen Z: Current status of treatment for chronic hepatitis C virus infection. Drugs Today (Barc). 2012, 48: 219-231.
Article
Google Scholar
Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ: Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002, 136: 288-292. 10.7326/0003-4819-136-4-200202190-00008.
Article
PubMed
Google Scholar
Robek MD, Wieland SF, Chisari FV: Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol. 2002, 76: 3570-3574. 10.1128/JVI.76.7.3570-3574.2002.
Article
PubMed Central
PubMed
Google Scholar
Janeway CA, Medzhitov R: Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol. 1998, 10: 349-350. 10.1006/smim.1998.0142.
Article
PubMed
Google Scholar
Iwasaki A, Medzhitov R: Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004, 5: 987-995. 10.1038/ni1112.
Article
PubMed
Google Scholar
Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell. 2006, 124: 783-801. 10.1016/j.cell.2006.02.015.
Article
PubMed
Google Scholar
Sioud M: Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med. 2006, 12: 167-176. 10.1016/j.molmed.2006.02.004.
Article
PubMed
Google Scholar
West AP, Koblansky AA, Ghosh S: Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol. 2006, 22: 409-437. 10.1146/annurev.cellbio.21.122303.115827.
Article
PubMed
Google Scholar
Prinz M, Heikenwalder M, Schwarz P, Takeda K, Akira S, Aguzzi A: Prion pathogenesis in the absence of Toll-like receptor signalling. EMBO Rep. 2003, 4: 195-199. 10.1038/sj.embor.embor731.
Article
PubMed Central
PubMed
Google Scholar
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001, 413: 732-738. 10.1038/35099560.
Article
PubMed
Google Scholar
Schwabe RF, Seki E, Brenner DA: Toll-like receptor signaling in the liver. Gastroenterology. 2006, 130: 1886-1900. 10.1053/j.gastro.2006.01.038.
Article
PubMed
Google Scholar
Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C: Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004, 303: 1529-1531. 10.1126/science.1093616.
Article
PubMed
Google Scholar
Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA: Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A. 2004, 101: 5598-5603. 10.1073/pnas.0400937101.
Article
PubMed Central
PubMed
Google Scholar
Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. Nature. 2000, 408: 740-745. 10.1038/35047123.
Article
PubMed
Google Scholar
Baccarella A, Fontana MF, Chen EC, Kim CC: Toll-like receptor 7 mediates early innate immune responses to malaria. Infect Immun. 2013, 81: 4431-4442. 10.1128/IAI.00923-13.
Article
PubMed Central
PubMed
Google Scholar
McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, Borozan I, Xie G, Selzner N, Heathcote EJ, Siminovitch K: Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology. 2012, 142: 1122-1131. 10.1053/j.gastro.2012.01.028. e1121
Article
PubMed
Google Scholar
Lee MS, Kim YJ: Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem. 2007, 76: 447-480. 10.1146/annurev.biochem.76.060605.122847.
Article
PubMed
Google Scholar
Gay NJ, Gangloff M: Structure and function of Toll receptors and their ligands. Annu Rev Biochem. 2007, 76: 141-165. 10.1146/annurev.biochem.76.060305.151318.
Article
PubMed
Google Scholar
Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature. 1998, 392: 245-252. 10.1038/32588.
Article
PubMed
Google Scholar
Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R: Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001, 2: 947-950. 10.1038/ni712.
Article
PubMed
Google Scholar
Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, Ito D, Azuma M: CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol. 1995, 154: 97-105.
PubMed
Google Scholar
Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, Trinchieri G: Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med. 2005, 201: 1157-1167. 10.1084/jem.20041930.
Article
PubMed Central
PubMed
Google Scholar
Seki E, Brenner DA: Toll-like receptors and adaptor molecules in liver disease: update. Hepatology. 2008, 48: 322-335. 10.1002/hep.22306.
Article
PubMed
Google Scholar
Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001, 2: 675-680. 10.1038/90609.
Article
PubMed
Google Scholar
Shu SA, Lian ZX, Chuang YH, Yang GX, Moritoki Y, Comstock SS, Zhong RQ, Ansari AA, Liu YJ, Gershwin ME: The role of CD11c(+) hepatic dendritic cells in the induction of innate immune responses. Clin Exp Immunol. 2007, 149: 335-343. 10.1111/j.1365-2249.2007.03419.x.
Article
PubMed Central
PubMed
Google Scholar
Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003, 3: 133-146. 10.1038/nri1001.
Article
PubMed
Google Scholar
Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol. 2003, 21: 335-376. 10.1146/annurev.immunol.21.120601.141126.
Article
PubMed
Google Scholar
Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S: Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol. 2001, 166: 5688-5694. 10.4049/jimmunol.166.9.5688.
Article
PubMed
Google Scholar
Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, Ozaki Y, Tomizawa H, Akira S, Fukuhara S: Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med. 2002, 195: 1507-1512. 10.1084/jem.20020207.
Article
PubMed Central
PubMed
Google Scholar
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006, 144: 705-714. 10.7326/0003-4819-144-10-200605160-00004.
Article
PubMed
Google Scholar
Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009, 49: 1335-1374. 10.1002/hep.22759.
Article
PubMed
Google Scholar
Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ: The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992, 327: 1899-1905. 10.1056/NEJM199212313272702.
Article
PubMed
Google Scholar
Rustgi VK: The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007, 42: 513-521. 10.1007/s00535-007-2064-6.
Article
PubMed
Google Scholar
Di Bisceglie AM: Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000, 31: 1014-1018. 10.1053/he.2000.5762.
Article
PubMed
Google Scholar
Lavanchy D: Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011, 17: 107-115. 10.1111/j.1469-0691.2010.03432.x.
Article
PubMed
Google Scholar
Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL: Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009, 137: 1680-1686. 10.1053/j.gastro.2009.07.047.
Article
PubMed Central
PubMed
Google Scholar
American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) Recommendations for Testing, Managing and Treating Hepatitis C. http://www.hcvguidelines.org Accessed April 21, 2014
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchinson JG, Sheikh AM, Younossi Z, Gane EJ: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013, 368: 1878-1887. 10.1056/NEJMoa1214853.
Article
PubMed
Google Scholar
Rehermann B: Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009, 119: 1745-1754. 10.1172/JCI39133.
Article
PubMed Central
PubMed
Google Scholar
Narita M, Watanabe N, Yamahira A, Hashimoto S, Tochiki N, Saitoh A, Kaji M, Nakamura T, Furukawa T, Toba K, Fuse I, Aizawa Y, Takahashi M: A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naive T cells. Leuk Res. 2009, 33: 1224-1232. 10.1016/j.leukres.2009.03.047.
Article
PubMed
Google Scholar
Zhang S, Kodys K, Babcock GJ, Szabo G: CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha. Hepatology. 2013, 58: 940-949. 10.1002/hep.25827.
Article
PubMed Central
PubMed
Google Scholar
Meissner EGOA, Polis MA, Kottilil S: Intrahepatic Changes in the Endogenous Interferon Response are Associated with SVR in Chronic Hepatitis C, Genotype-1 Subjects Treated with Sofosbuvir and Ribavirin. 2013, Washington, D.C.: In American Association for the Study of Liver Diseases
Google Scholar
Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, Steffy KR, Bauman LA, Kerr BM, Averett DR: Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology. 2005, 42: 724-731. 10.1002/hep.20839.
Article
PubMed
Google Scholar
Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng TC: Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol. 2007, 47: 174-182. 10.1016/j.jhep.2007.02.025.
Article
PubMed
Google Scholar
Meyer T, Surber C, French LE, Stockfleth E: Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs. 2013, 22: 149-159. 10.1517/13543784.2013.749236.
Article
PubMed
Google Scholar
Harrison LI, Astry C, Kumar S, Yunis C: Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol. 2007, 47: 962-969. 10.1177/0091270007303766.
Article
PubMed
Google Scholar
Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey TP, Colman P, Kumar V, Cheng JB, Wright K, Srinivasan S, Rana K, Craig C, Horscroft N, Perros M, Westby IM, Webster R, van der Ryst E: The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011, 89: 821-829. 10.1038/clpt.2011.60.
Article
PubMed
Google Scholar
Bergmann JF, de Bruijne J, Hotho DM, de Knegt RJ, Boonstra A, Weegink CJ, van Vliet AA, van de Wetering J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Janssen HL, Reesink HW: Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther. 2011, 34: 443-453. 10.1111/j.1365-2036.2011.04745.x.
Article
PubMed
Google Scholar
Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005, 54: 1-31.
PubMed
Google Scholar
Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004, 11: 97-107. 10.1046/j.1365-2893.2003.00487.x.
Article
PubMed
Google Scholar
McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS: Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health. 1999, 89: 14-18. 10.2105/AJPH.89.1.14.
Article
PubMed Central
PubMed
Google Scholar
Beasley RP: Hepatitis B virus. The major etiology of hepatocellular carcinoma Cancer. 1988, 61: 1942-1956.
PubMed
Google Scholar
Bosch FX, Ribes J, Cleries R, Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005, 9: 191-211. 10.1016/j.cld.2004.12.009. v
Article
PubMed
Google Scholar
Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology. 2009, 50: 661-662. 10.1002/hep.23190.
Article
PubMed
Google Scholar
Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS: Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006, 44: 703-712. 10.1002/hep.21290.
Article
PubMed
Google Scholar
Wieland S, Thimme R, Purcell RH, Chisari FV: Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A. 2004, 101: 6669-6674. 10.1073/pnas.0401771101.
Article
PubMed Central
PubMed
Google Scholar
Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, Clementi M, Colombo M: A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997, 26: 1621-1625. 10.1002/hep.510260634.
Article
PubMed
Google Scholar
Isogawa M, Robek MD, Furuichi Y, Chisari FV: Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005, 79: 7269-7272. 10.1128/JVI.79.11.7269-7272.2005.
Article
PubMed Central
PubMed
Google Scholar
Wieland SF, Guidotti LG, Chisari FV: Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol. 2000, 74: 4165-4173. 10.1128/JVI.74.9.4165-4173.2000.
Article
PubMed Central
PubMed
Google Scholar
Zhang X, Kraft A, Broering R, Schlaak JF, Dittmer U, Lu M: Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin Drug Discov. 2012, 7: 597-611. 10.1517/17460441.2012.689281.
Article
PubMed
Google Scholar
Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, Rodgers S, Kurtovic J, Chang J, Lewin S, Desmond P, Locarnini S: Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology. 2007, 45: 102-110. 10.1002/hep.21482.
Article
PubMed
Google Scholar
Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A: The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol. 2011, 55: 762-769. 10.1016/j.jhep.2010.12.042.
Article
PubMed
Google Scholar
Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, Zhang Q, Wang J, Zhang Z, Shen F, Yuan Z: Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol. 2008, 128: 400-408. 10.1016/j.clim.2008.04.006.
Article
PubMed
Google Scholar
Wang H, Ryu WS: Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog. 2010, 6: e1000986-10.1371/journal.ppat.1000986.
Article
PubMed Central
PubMed
Google Scholar
Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z: Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol. 2010, 91: 2080-2090. 10.1099/vir.0.020552-0.
Article
PubMed
Google Scholar
Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF: Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology. 2009, 49: 1132-1140. 10.1002/hep.22751.
Article
PubMed
Google Scholar
Gane EJSE, Gordon SC, Gruener D: Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B. 2013, Washington DC: American Association for the Study of Liver Disease
Google Scholar
Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, Fosdick A, Frey CR, Zheng J, Wolfgang G, Halcomb RL, Tumas DB: GS-9620, an o ral a gonist of Toll-l ike r eceptor-7 induces prolonged suppression of Hepatitis B Virus in chronically infected chimpanzees. Gastroenterology. 2013, 144: 1508-1517. 10.1053/j.gastro.2013.02.003.
Article
PubMed Central
PubMed
Google Scholar
Lopatin U, Wolfgang G, Tumas D, Frey CR, Ohmstede C, Hesselgesser J, Kearney B, Moorehead L, Subramanian GM, McHutchison JG: Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antivir Ther. 2013, 18: 409-418. 10.3851/IMP2548.
Article
PubMed
Google Scholar